A Phase 2 interventional study of Lenvatinib and Pembrolizumab in Squamous Cell Carcinoma of Head and Neck, sponsored by Merck Sharp & Dohme LLC. Completed at 120 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck — 18 open to participants now, 32 under way, 2 of them phase 3. pembrolizumab · Squamous Cell Carcinoma of Head and Neck.
Among the 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck, this one is the 2nd largest by enrollment, is one of 5 that started in 2020, is one of 44 in phase 2, and was the 31st registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →18 of the 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck are open now, in 5 countries. Recruiting first, the newest first:
Brown University · Sites in United States
Ages 65+
Emory University · Sites in United States
Ages 18+
National University Hospital, Singapore · Sites in Singapore
Ages 21–99
University of Leipzig · Sites in Germany
Ages 18–70
University of California, Davis · Sites in United States
Ages 18+
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 47 · Phase 3 5 · Phase 4 1
First in 2014; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 408 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 50 across the 63 interventional studies. Of the 28 that completed or were terminated, 18 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 63 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
12 studies in Squamous Cell Carcinoma of Head and Neck by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 12 studies in Squamous Cell Carcinoma of Head and Neck by Merck & Co., Inc, this one is the 4th largest by enrollment, is one of 5 that started in 2020, is one of 7 in phase 2, and was the 8th registered.
Merck & Co., Inc’s Squamous Cell Carcinoma of Head and Neck studies by the year they started, since 2003.
9 of the studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06998069Phase 3Brown UniversityHead and Neck Cancer Study Project in the Geriatric Population | 2026-12-01 |
| NCT06102395Phase 3Beijing Tongren HospitalEvaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC | 2027-04-30 |
| NCT06580054University of Michigan Rogel Cancer CenterPembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma | 2026-12 |
| NCT06211335University of California, DavisLosartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma | 2026-12 |
| NCT04754321Ohio State University Comprehensive Cancer CenterCombining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
Among Merck & Co., Inc’s 12 in Squamous Cell Carcinoma of Head and Neck:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer has spread to other parts of the body (metastatic). Some people with recurrent or metastatic head and neck cancer are treated with chemotherapy and immunotherapy, but the cancer gets worse.
The goal of this study is to learn if more people who receive lenvatinib and pembrolizumab have a better overall survival rate than people who receive standard chemotherapy treatment.
With Amendment 7, participants will discontinue lenvatinib and pembrolizumab and lenvatinib monotherapy, unless discussed with the Sponsor.
A protocol-specified periodic safety review was completed with a data cut-off of 31-May-2024 (Primary Completion Date) and served as the final analysis of the primary outcome measure. Per protocol, 34 participants enrolled after the primary completion date and will be analyzed in the End of Trial analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male participants are eligible to participate if they agree to the following during the intervention period and for at least 1 week after the last dose of lenvatinib, 3 months after the last dose of capecitabine and paclitaxel, and 6 months after the last dose of docetaxel:
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be treated with the combination of lenvatinib (once daily 20 mg oral dose) plus pembrolizumab (200 mg 30-minute intravenous (IV) infusion on Day 1 of each 21-day cycle for 35 cycles), until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met. Participants may receive up to an additional 17 cycles of pembrolizumab as Second Course treatment, with or without lenvatinib.
Drug: Lenvatinib · Biological: Pembrolizumab
Participants will be treated with investigator's choice of standard of care (SOC) chemotherapy (docetaxel, paclitaxel, cetuximab, or capecitabine) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.
Drug: Docetaxel · Drug: Capecitabine · Drug: Paclitaxel · Drug: Cetuximab
Participants will be treated with lenvatinib monotherapy (once daily 24 mg oral dose) until centrally verified disease progression, or until a protocol-specified discontinuation criterion is met.
Drug: Lenvatinib
20 mg once daily, taken as oral capsules
Also known as: LENVIMA®, MK-7902, E7080
200 mg 30-minute IV infusion on day 1 of each 21-day cycle
Also known as: KEYTRUDA®, MK-3475, SCH 900475
75 mg/m\^2 administered as an IV infusion on day 1 of each 21-day cycle
Also known as: TAXOTERE®
1250 mg/m\^2 twice daily on days 1-14 of each 21-day cycle, taken as oral tablets
Also known as: Xeloda®
80 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
Also known as: Taxol
400 mg/m\^2 loading dose, followed by 250 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
Also known as: ERBITUX®
24 mg once daily, taken as oral capsules
Also known as: LENVIMA®, MK-7902, E7080
Overall Survival (OS)
OS was defined as the time from randomization to death due to any cause.
Time frame: Up to approximately 45 months
Progression-Free Survival (PFS)
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD.
Time frame: Up to approximately 45 months
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who had a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
Time frame: Up to approximately 45 months
Duration of Response (DOR)
DOR was defined as the time from the first documented evidence of complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified RECIST 1.1 as assessed by BICR.
Time frame: Up to approximately 45 months
Number of Participants Who Experienced One or More Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE was presented.
Time frame: Up to approximately 5 years
Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE was presented.
Time frame: Up to approximately 5 years
| Milestone | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy |
|---|---|---|---|
| Started | 144 | 142 | 88 |
| Treated | 143 | 140 | 88 |
| Switched over to pembrolizumab + lenvatinib | 0 | 61 | 18 |
| Switched over to pembrolizumab | 0 | 1 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 144 | 142 | 88 |
| Withdrew: Death | 100 | 86 | 57 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 3 |
| Withdrew: Participant ongoing in study | 41 | 53 | 28 |
OS was defined as the time from randomization to death due to any cause.
| Months | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy |
|---|---|---|---|
| Overall Survival (OS) | 8.4 (6.9 to 10.3) | 11.3 (9.8 to 14.4) | — |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD.
| Months | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy |
|---|---|---|---|
| Progression-Free Survival (PFS) | 3.0 (2.8 to 3.9) | 2.8 (2.6 to 4.0) | — |
ORR was defined as the percentage of participants who had a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
| Percentage of Participants | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy |
|---|---|---|---|
| Objective Response Rate (ORR) | 13.9 (8.7 to 20.6) | 20.4 (14.1 to 28.0) | — |
DOR was defined as the time from the first documented evidence of complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to modified RECIST 1.1 as assessed by BICR.
| Months | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy |
|---|---|---|---|
| Duration of Response (DOR) | 4.1 (3.6 to 7.9) | 5.9 (3.7 to 11.8) | — |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE was presented.
Results for this outcome have not been posted.
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE was presented.
Results for this outcome have not been posted.
Collected over Up to approximately 45 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenvatinib + Pembrolizumab | 103/144 (71.5%) | 86/143 (60.1%) | 139/143 (97.2%) |
| SOC Chemotherapy | 42/142 (29.6%) | 57/140 (40.7%) | 135/140 (96.4%) |
| Lenvatinib Monotherapy | 50/88 (56.8%) | 45/88 (51.1%) | 80/88 (90.9%) |
| SOC Chemotherapy Switched Over to Pembrolizumab+Lenvatinib | 44/61 (72.1%) | 27/61 (44.3%) | 55/61 (90.2%) |
| SOC Chemotherapy Switched Over to Pembrolizumab | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Lenvatinib Switched Over to Pembrolizumab+Lenvatinib | 10/18 (55.6%) | 6/18 (33.3%) | 15/18 (83.3%) |
| Event | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy | SOC Chemotherapy Switched Over to Pembrolizumab+Lenvatinib | SOC Chemotherapy Switched Over to Pembrolizumab | Lenvatinib Switched Over to Pembrolizumab+Lenvatinib |
|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 20/143 | 8/140 | 4/88 | 5/61 | 1/1 | 2/18 |
| SepsisInfections and infestations | 3/143 | 1/140 | 1/88 | 1/61 | 0/1 | 2/18 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/143 | 3/140 | 6/88 | 1/61 | 0/1 | 1/18 |
| Cardiac tamponadeCardiac disorders | 0/143 | 0/140 | 0/88 | 0/61 | 0/1 | 1/18 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/143 | 0/140 | 0/88 | 0/61 | 0/1 | 1/18 |
| Large intestine infectionInfections and infestations | 0/143 | 0/140 | 0/88 | 0/61 | 0/1 | 1/18 |
| HypotensionVascular disorders | 0/143 | 0/140 | 0/88 | 0/61 | 0/1 | 1/18 |
| DysphagiaGastrointestinal disorders | 4/143 | 2/140 | 3/88 | 3/61 | 0/1 | 0/18 |
| PyrexiaGeneral disorders | 1/143 | 1/140 | 0/88 | 3/61 | 0/1 | 0/18 |
| Pneumonia aspirationInfections and infestations | 4/143 | 2/140 | 2/88 | 3/61 | 0/1 | 0/18 |
| Event | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy | SOC Chemotherapy Switched Over to Pembrolizumab+Lenvatinib | SOC Chemotherapy Switched Over to Pembrolizumab | Lenvatinib Switched Over to Pembrolizumab+Lenvatinib |
|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 9/143 | 2/140 | 4/88 | 2/61 | 1/1 | 0/18 |
| Alanine aminotransferase increasedInvestigations | 11/143 | 8/140 | 5/88 | 2/61 | 1/1 | 1/18 |
| Aspartate aminotransferase increasedInvestigations | 13/143 | 11/140 | 9/88 | 6/61 | 1/1 | 2/18 |
| HyponatraemiaMetabolism and nutrition disorders | 8/143 | 4/140 | 9/88 | 1/61 | 1/1 | 2/18 |
| Urinary retentionRenal and urinary disorders | 1/143 | 2/140 | 1/88 | 0/61 | 1/1 | 0/18 |
| HypertensionVascular disorders | 60/143 | 5/140 | 34/88 | 17/61 | 1/1 | 1/18 |
| StomatitisGastrointestinal disorders | 52/143 | 28/140 | 26/88 | 21/61 | 0/1 | 1/18 |
| HypothyroidismEndocrine disorders | 49/143 | 12/140 | 28/88 | 15/61 | 0/1 | 1/18 |
| Weight decreasedInvestigations | 26/143 | 22/140 | 27/88 | 7/61 | 0/1 | 2/18 |
| DiarrhoeaGastrointestinal disorders | 38/143 | 26/140 | 25/88 | 15/61 | 0/1 | 4/18 |
Per protocol, analysis population consisted of all participants randomized by the primary completion data cut-off.
| Age, Continuous(Years) | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy | Total |
|---|---|---|---|---|
| Mean | 62.3 ± 9.0 | 61.4 ± 10.0 | 59.9 ± 9.3 | 61.4 ± 9.5 |
| Sex: Female, Male(Participants) | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy | Total |
|---|---|---|---|---|
| Female | 18 | 19 | 14 | 51 |
| Male | 126 | 123 | 74 | 323 |
| Ethnicity (NIH/OMB)(Participants) | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 | 12 |
| Not Hispanic or Latino | 139 | 137 | 82 | 358 |
| Unknown or Not Reported | 2 | 2 | 0 | 4 |
| Race (NIH/OMB)(Participants) | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 | 6 |
| Asian | 35 | 40 | 25 | 100 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 2 | 8 |
| White | 104 | 96 | 57 | 257 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 1 | 3 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy | Total |
|---|---|---|---|---|
| ECOG = 0 | 52 | 58 | 32 | 142 |
| ECOG = 1 | 92 | 84 | 56 | 232 |
| Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline(Participants) | Lenvatinib + Pembrolizumab | SOC Chemotherapy | Lenvatinib Monotherapy | Total |
|---|---|---|---|---|
| TPS = <50% | 121 | 120 | 74 | 315 |
| TPS = ≥ 50% | 23 | 22 | 14 | 59 |
Showing the first 100 of 120 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Aug 2020 to primary completion in May 2024, 45 months.
Results were first posted in May 2025, 11 months after primary completion.
Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 45 months is close to that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenvatinib · Pembrolizumab
Squamous Cell Carcinoma of Head and Neck →